The many faces of interleukin‐17 in inflammatory skin diseases

Interleukin (IL)‐17 is an emerging target for inflammatory skin disorders. Given the remarkable success of its therapeutic inhibition in psoriasis, the pathogenic role of this cytokine is being explored in other immune‐mediated diseases. Interestingly, IL‐17 is linked to particular skin conditions where its activation coincides with disease flares. The leading hypothesis for its contribution to proinflammatory signalling cascades is driving inflammasome activation. However, IL‐17 stimulation also releases a range of noninflammasome‐related cytokines from human skin. Furthermore, a role in cytotoxic responses and an important interplay with the microbiome is hypothesized. While treatment failure would be surprising in neutrophilic dermatoses, the picture might be more complex in lymphocyte‐mediated conditions. Nonetheless, increasing insights into the pathogenesis suggest that beneficial responses are also probable in the latter conditions. Study of this pathway in the skin reveals some intriguing aspects of the IL‐17‐related immunological network.

[1]  Robert W. Williams,et al.  Interleukin 17–producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice , 2008, Nature Immunology.

[2]  P. Meroni,et al.  Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement. , 2013, Arthritis and rheumatism.

[3]  F. Borgia,et al.  Serum interleukin 17, interleukin 23, and interleukin 10 values in children with atopic eczema/dermatitis syndrome (AEDS): association with clinical severity and phenotype. , 2015, Allergy and asthma proceedings.

[4]  M. Suárez-Fariñas,et al.  A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis. , 2016, The Journal of allergy and clinical immunology.

[5]  M. Furue,et al.  Mutual upregulation of endothelin‐1 and IL‐25 in atopic dermatitis , 2015, Allergy.

[6]  A. Bruce,et al.  Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis , 2011, The Journal of Immunology.

[7]  Thomas Korn,et al.  IL-17 and Th17 Cells. , 2009, Annual review of immunology.

[8]  Martin M. Schumacher,et al.  Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis , 2015, Experimental dermatology.

[9]  T. Naka,et al.  Dysregulation of melanocyte function by Th17‐related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris , 2012, Pigment cell & melanoma research.

[10]  J. Kolls,et al.  Targeting IL-17 and TH17 cells in chronic inflammation , 2012, Nature Reviews Drug Discovery.

[11]  M. Atwa,et al.  T‐helper 17 cytokines (interleukins 17, 21, 22, and 6, and tumor necrosis factor‐α) in patients with alopecia areata: association with clinical type and severity , 2016, International journal of dermatology.

[12]  F. Mackay,et al.  Clinical associations of serum interleukin-17 in systemic lupus erythematosus , 2013, Arthritis Research & Therapy.

[13]  S. Gaffen,et al.  IL-17–Mediated Immunity to the Opportunistic Fungal Pathogen Candida albicans , 2015, The Journal of Immunology.

[14]  M. Veldhoen,et al.  TGFbeta1, a "Jack of all trades": the link with pro-inflammatory IL-17-producing T cells. , 2006, Trends in immunology.

[15]  J. Ring,et al.  Differential in situ expression of IL-17 in skin diseases. , 2012, European journal of dermatology : EJD.

[16]  Marc Vandemeulebroecke,et al.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial , 2012, Gut.

[17]  D. Fanoni,et al.  Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome , 2014, Clinical and experimental immunology.

[18]  A. Fischer,et al.  Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis , 2011, The Journal of experimental medicine.

[19]  E. Alpsoy,et al.  IL-17A has an important role in the acute attacks of Behçet's disease. , 2010, The Journal of investigative dermatology.

[20]  M. Tauber,et al.  Alopecia areata developing during ustekinumab therapy: report of two cases. , 2013, EJD. European journal of dermatology.

[21]  B. Strober,et al.  Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. , 2015, The New England journal of medicine.

[22]  M. Suárez-Fariñas,et al.  Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. , 2015, The Journal of allergy and clinical immunology.

[23]  M. Lebwohl,et al.  Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials , 2015, The Lancet.

[24]  M. Suárez-Fariñas,et al.  Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis , 2013, The Journal of investigative dermatology.

[25]  D. Elashoff,et al.  Propionibacterium acnes induces an interleukin-17 response in acne vulgaris that is regulated by vitamin A and vitamin D , 2013, The Journal of investigative dermatology.

[26]  M. Netea,et al.  Compartmentalized Cytokine Responses in Hidradenitis Suppurativa , 2015, PloS one.

[27]  A. Gurney,et al.  IL‐17: prototype member of an emerging cytokine family , 2002, Journal of leukocyte biology.

[28]  T. Giner,et al.  Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa , 2016, The British journal of dermatology.

[29]  G. Seymour,et al.  Regulation of immune cells in oral lichen planus , 2015, Archives of Dermatological Research.

[30]  Zengtong Zhou,et al.  Expression of Foxp3 and interleukin-17 in lichen planus lesions with emphasis on difference in oral and cutaneous variants , 2014, Archives of Dermatological Research.

[31]  T. Buhl,et al.  Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways. , 2015, The Journal of investigative dermatology.

[32]  Annette Lee,et al.  Genome-wide association study in alopecia areata implicates both innate and adaptive immunity , 2010, Nature.

[33]  G. Firestein,et al.  Role of Interleukin 17 in Arthritis Chronicity through Survival of Synoviocytes via Regulation of Synoviolin Expression , 2010, PloS one.

[34]  F. Mantelli,et al.  T-helper 17 lymphocytes in ocular cicatricial pemphigoid , 2009, Molecular vision.

[35]  T. Dainichi,et al.  Lesional Th17 cells and regulatory T cells in bullous pemphigoid , 2011, Experimental dermatology.

[36]  O. Shaker,et al.  Role of interleukin‐17 in the pathogenesis of vitiligo , 2011, Clinical and experimental dermatology.

[37]  Marziyeh Aghazadeh,et al.  Serum Level of Interleukin 17 in Patients with Erosive and Non erosive Oral Lichen Planus , 2013, Journal of dental research, dental clinics, dental prospects.

[38]  J. Colombel,et al.  Secukinumab failure in Crohn's disease: the yeast connection? , 2012, Gut.

[39]  A. Georgescu,et al.  IL-17 in cutaneous lupus erythematosus. , 2010, European journal of internal medicine.

[40]  A. Paller,et al.  Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. , 2015, The Journal of allergy and clinical immunology.

[41]  A. Kijlstra,et al.  Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. , 2008, Investigative ophthalmology & visual science.

[42]  Feng Xu,et al.  Imbalance of T‐helper 17 and regulatory T cells in patients with alopecia areata , 2015, The Journal of dermatology.

[43]  S. Mehrotra,et al.  The Inducible Costimulator Augments Tc17 Cell Responses to Self and Tumor Tissue , 2015, The Journal of Immunology.

[44]  Hee-Ryung Cho,et al.  Association between IL17A/IL17RA Gene Polymorphisms and Susceptibility to Alopecia Areata in the Korean Population , 2012, Annals of dermatology.

[45]  S. Gaffen.  Structure and signalling in the IL-17 receptor family , 2009, Nature Reviews Immunology.

[46]  I. Bekeredjian-Ding,et al.  The Innate Immune Response Against Staphylococcus aureus. , 2015, Current topics in microbiology and immunology.

[47]  Jiyao Li,et al.  Analysis of oral microbial community and Th17‐associated cytokines in saliva of patients with oral lichen planus , 2015, Microbiology and immunology.

[48]  L. Rashed,et al.  T helper 17 and Tregs: a novel proposed mechanism for NB‐UVB in vitiligo , 2014, Experimental dermatology.

[49]  S. Androudi,et al.  Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. , 2013, Ophthalmology.

[50]  古賀 千律子.  Possible pathogenic role of Th17 cells for atopic dermatitis , 2011 .

[51]  D. Greco,et al.  IL-17/Th17 Pathway Is Activated in Acne Lesions , 2014, PloS one.

[52]  K. Ley,et al.  Homeostatic Regulation of Blood Neutrophil Counts , 2008, The Journal of Immunology.

[53]  M. Fujimoto,et al.  Impaired IL-17 Signaling Pathway Contributes to the Increased Collagen Expression in Scleroderma Fibroblasts , 2012, The Journal of Immunology.

[54]  M. Rosenblum,et al.  An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. , 2014, Journal of the American Academy of Dermatology.

[55]  B. Elewski,et al.  Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.

[56]  O. Shaker,et al.  Possible role of interleukin‐17 in the pathogenesis of lichen planus , 2012, The British journal of dermatology.

[57]  A. Khamesipour,et al.  The effect of conventional immunosuppressive therapy on cytokine serum levels in pemphigus vulgaris patients. , 2014, Iranian journal of allergy, asthma, and immunology.

[58]  Kathleen M. Smith,et al.  Development, cytokine profile and function of human interleukin 17–producing helper T cells , 2007, Nature Immunology.

[59]  Lai Wei,et al.  IL-21 Is Produced by Th17 Cells and Drives IL-17 Production in a STAT3-dependent Manner* , 2007, Journal of Biological Chemistry.

[60]  G. Pier,et al.  Topical Neutralization of Interleukin-17 during Experimental Pseudomonas aeruginosa Corneal Infection Promotes Bacterial Clearance and Reduces Pathology , 2012, Infection and Immunity.

[61]  A. Gottlieb,et al.  Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2015, The Lancet.

[62]  Xinyang Song,et al.  The activation and regulation of IL-17 receptor mediated signaling. , 2013, Cytokine.

[63]  C. Terao,et al.  Neutrophils Are Essential As A Source Of Il-17 In The Effector Phase Of Arthritis , 2013, PloS one.

[64]  Alpana Sharma,et al.  Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-β) in patients with vitiligo. , 2012, Journal of the American Academy of Dermatology.

[65]  Lisa C. Zaba,et al.  Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways , 2008, The British journal of dermatology.

[66]  C. Vestergaard,et al.  IL-25 in atopic dermatitis: a possible link between inflammation and skin barrier dysfunction? , 2011, The Journal of investigative dermatology.

[67]  M. Lebwohl,et al.  Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. , 2015, The Journal of allergy and clinical immunology.

[68]  T. Wynn,et al.  Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[69]  J. Carucci,et al.  Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis1 , 2008, The Journal of Immunology.

[70]  M. Schaller,et al.  Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. , 2011, Archives of dermatology.

[71]  C. Weaver,et al.  Neutrophils Produce Interleukin 17A (IL-17A) in a Dectin-1- and IL-23-Dependent Manner during Invasive Fungal Infection , 2011, Infection and Immunity.

[72]  Massimo Gadina,et al.  Jakpot! New small molecules in autoimmune and inflammatory diseases , 2014, Experimental dermatology.

[73]  V. Engelhard,et al.  Immune responses in a mouse model of vitiligo with spontaneous epidermal de‐ and repigmentation , 2014, Pigment cell & melanoma research.

[74]  S. Batra,et al.  IFN-γ induction by neutrophil-derived IL-17A homodimer augments pulmonary antibacterial defense , 2015, Mucosal Immunology.

[75]  E. Barillot,et al.  A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses , 2008, Nature Immunology.

[76]  R. Hegazy,et al.  Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: a case- controlled study on eighty-four patients. , 2013, European journal of dermatology : EJD.